On December 1, 2025, a VA memo cut off Veterans' access to annular fibrin injections — a minimally invasive treatment for chronic back pain. Add your name to demand it be restored.
Takes under 60 seconds · All signers welcome.
When medications, physical therapy, and injections stop working, Veterans are funneled to a single option: invasive, irreversible surgery. Fusion permanently alters spinal mechanics, carries real surgical risk, and often leads to adjacent segment breakdown over time.
There was a logical step between failed conservative care and irreversible surgery. Annular fibrin injection (AFI), a minimally invasive, outpatient procedure — could seal the disc tear at the source and restore function without hardware or hospitalization. It does not eliminate surgery as a future option.
On December 1, 2025, VA Clinical Determination CDI 00059 eliminated AFI as an option — designating AFI as "investigational, experimental, and not medically necessary" with no clinical panel, no phase-out period, and no alternative pathway offered to Veterans already mid-treatment. That designation conflicts with over two decades of published evidence. The science below explains why.
A targeted, minimally invasive treatment that uses the body's own biological processes — no surgery, no hardware, no hospitalization.
Fibrin is the body's natural structural protein used in wound healing. First identified in 1666 by Italian scientist Marcello Malpighi, fibrin forms when the body activates fibrinogen — a protein that lies dormant in the blood until injury triggers it to assemble into a tough, insoluble fiber mesh. When you bleed, that mesh becomes the framework of a blood clot — sealing the wound and initiating repair. Fibrin has been used in medicine since World War II — first applied to soldiers with battlefield wounds. The modern commercial form has been FDA-approved since 1998, indicated to control bleeding and seal tissue when conventional techniques fall short. AFI applies the same protein, fibrin, to the damaged spinal disc.
The spinal disc has two components: an outer ring — the annulus fibrosus — and an inner core — the nucleus pulposus. The annulus fibrosus is built from layered collagen fibers arranged in a cross-hatch pattern, giving the disc its strength and the ability to withstand the forces of movement and load. The nucleus pulposus, by contrast, is a gel-like core of water, proteoglycans, and collagen that acts as a shock absorber, distributing compressive forces evenly across the disc. When the outer ring tears or weakens from injury, the disc can bulge outward, herniate, or allow the inner material to leak and irritate nearby nerves. Any of these can cause significant chronic back pain and radiculopathy. Unlike bone and muscle, the disc is avascular, lacking a direct blood supply, and may not easily heal. If these injuries do not respond to non-operative care, one can consider annular fibrin injections.
Diagnostic Annulogram: A contrast dye is injected into the annulus fibrosus under live X-ray guidance. Dye that escapes through the annulus confirms the location and extent of the tear — identifying pathology that MRI alone may not identify.
Fibrin Sealant Injection: Through the same needle access, fibrin sealant is delivered into the damaged annulus. The components polymerize instantly on contact, forming a viscoelastic fibrin mesh that seals the annular defect and creates a biological scaffold — stimulating collagen deposition and natural tissue repair.
Pauza et al. (2024), an 827-patient prospective registry, showed sustained, statistically significant improvements in pain and function through 36 months. At 12 months, 50% of patients achieved a Minimal Clinically Important Difference in the Oswestry Disability Index — of those, 74% saw ≥50% improvement and 40% saw ≥75% improvement. Patient satisfaction was 67–74% across all follow-up points, and function scores improved by more than 30% at 6 months, sustained through 3 years.
Below is a timeline of AFI research, from early porcine disc repair studies to clinical trials, the annular fibrin treatment, its commercial branding as Discseel®, and the VA's 2025 coverage determination that eliminated access for Veterans.
Click any point on the timeline to learn more
The VHA Office of Integrated Veteran Care issued Coverage Determination IVC-CDI-00059, effective December 1, 2025, designating annular fibrin injections as investigational, experimental, and not medically necessary. The VA acknowledges the 2024 Annular Fibrin Registry — yet concludes that real-world evidence, a lack of on-label FDA indication, is not enough. That stance sits at odds with the direction Congress set in the 21st Century Cures Act, and is inconsistent with the VA's coverage of other commonly performed off-label procedures, such as epidural steroid injections.
The VA's CDI also conflates the Biostat intranuclear approach with an intra-annular approach — two procedures the memo does not treat as methodologically distinct.
1. VHA Office of Integrated Veteran Care. Coverage Determination IVC-CDI-00059: Annular Fibrin Injections. US Department of Veterans Affairs; effective December 1, 2025.
2. Ju DG, Kanim LE, Bae HW. Is there clinical improvement associated with intradiscal therapies? A comparison across randomized controlled studies. Global Spine Journal. 2022;12(5):756–764. doi:10.1177/2192568220963058.
With CDI 00059 in effect, no Veteran can recieve coverage for annular fibrin injections — regardless of diagnosis, disease severity, or physician recommendation. Trained physicians how treated over 10,000 civilians. The VA's determination closes the only realistic coverage pathway for Veterans.
Veterans who have exhausted conservative care — physical therapy, epidural steroid injections, facet procedures — and who are not surgical candidates are left with few remaining options within the VA system. Those who can afford self-pay costs may access treatment. Those who cannot afford it have no path to treatment at all.
1. VHA Office of Integrated Veteran Care. Coverage Determination IVC-CDI-00059: Annular Fibrin Injections. US Department of Veterans Affairs; effective December 1, 2025.
2. 38 U.S.C. § 1710(a)(1). Eligibility for hospital care, medical services, and nursing home care.
3. Veterans Access, Choice, and Accountability Act of 2014, as amended. MISSION Act, 38 U.S.C. § 1703(d)(1)(E). Eligibility for community care when VA cannot provide timely or geographically accessible care.
4. 38 U.S.C. § 1703(n)(1). Prohibition on limitations — Secretary shall not limit types of care if in the best medical interest of the veteran as determined by the veteran and their health care provider.
5. 35 U.S.C. § 287(c). Limitation on damages and other remedies — medical activity exception.
When a Veteran and their physician agree that annular fibrin injection is the right treatment, federal law was written to protect that decision. The MISSION Act requires the VA to provide community care when:
"The covered veteran and the covered veteran's referring clinician agree that furnishing care and services through a non-Department entity or provider would be in the best medical interest of the covered veteran based upon criteria developed by the Secretary." — 38 U.S.C. § 1703(d)(1)(E), MISSION Act (Caring for Our Veterans Act of 2018)
Congress also built in a clear limit on how far the VA can go in restricting that care:
"The Secretary shall not limit the types of hospital care, medical services, or extended care services covered veterans may receive under this section if it is in the best medical interest of the veteran to receive such hospital care, medical services, or extended care services, as determined by the veteran and the veteran's health care provider." — 38 U.S.C. § 1703(n)(1), MISSION Act (Caring for Our Veterans Act of 2018)
CDI 00059 conflicts with the second provision. By categorically excluding annular fibrin injection regardless of individual circumstance, it imposes exactly the kind of blanket treatment restriction § 1703(n)(1) was written to prevent — one made by administrative policy before any Veteran or physician is ever heard.
Tisseel® fibrin sealant has been FDA-approved since 1998 with over 25 years of routine surgical use. The same sealant is already applied off-label during VA-covered spinal surgeries (laminectomies, fusions). Simultaneously authorizing those procedures while denying annular fibrin injections is contradictory.
The 21st Century Cures Act (21 U.S.C. § 355g) directed the FDA to establish a framework recognizing real-world evidence — including patient registries — as a valid basis for regulatory decision-making. It is our opinion, that the 827-patient annular fibrin registry meets that standard. The VA already accepts comparable registry and observational evidence for lumbar fusion, disc arthroplasty, and spinal cord stimulators. Applying a stricter evidentiary standard to AFI alone, without explanation, is an inconsistency the VA has not justified.
Forcing Veterans from AFI directly to lumbar fusion — which carries 22.7% cumulative revision rates at 10 years and 25–40% adjacent segment disease — compounds costs across both healthcare and disability compensation. Preliminary modeling projects significant savings per 100 Veterans when AFI is used as a treatment step before fusion. As many Veterans may not require subsequent spinal fusion.
Primum non nocere — first, do no harm.
When a physician determines that AFI is the appropriate next step and a Veteran provides informed consent, denying that treatment overrides the. Ethically, a procedure with lower invasiveness and lower complication rate (annular fibrin) should be chosen before a more invasive, more complex procedure (spinal fusion).
Veterans with personal resources can access AFI as a self-pay service. Those entirely dependent on VA coverage — often the most service-connected and financially at risk — cannot. A federally funded system designed to serve those who served should not replicate private-market access disparities.
Disc degeneration is progressive. Denying AFI during the early intervention window may allow significant disease progresssion to occur. With AFI then no longer an option.
Three ways you can help Veterans access annular fibrin injections. Every signature and every message to Congress moves the needle.
Add your name to our petition urging the VA to reconsider CDI 00059 and restore Veterans' access to a treatment supported by meaningful evidence and recommended by their physicians. Signatures from Veterans, family members, healthcare providers, and advocates all count.
Join Veterans, families, and advocates calling for change — every voice strengthens the case.
Sign the PetitionCongressional pressure is the most effective lever for VA policy change. Click below to find your senators and representative. We have provided a template message explaining why CDI 00059 must be reconsidered.
Share this page with Veterans, friends, and family. Many Veterans — and their families — don't know this treatment exists or that the VA is blocking it. Sharing on social media, in Veteran community groups, or simply forwarding this URL can make an enormous difference.